Restatement of the Consolidated Financial Statements - Restatement of Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (36,224)	$ (178)	$ 1,804	$ 4,619	$ 4,276	$ 44,051	$ 10,402	$ 5,998	$ (29,979)	$ 64,727	$ 390
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation									5,882	4,087	3,333
Amortization of intangible assets									1,034	1,678	2,137
Amortization of inventory fair value step-up									0	203	1,485
Amortization of deferred financing costs									137	176	151
Change in fair value of earn-out consideration									0	(3,560)	(1,650)
Share-based compensation									14,768	21,195	17,732
Change in deferred income taxes									25,541	(26,670)	(5,992)
Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in:
Accounts receivable									0	(479)	73
Inventory									(6,519)	2,747	(895)
Prepaid expenses									(4,548)	(305)	(793)
Other assets									3,562	225	(1,567)
Accounts payable									6,585	(1,324)	(3,478)
Accrued compensation									2,083	8,397	(2,586)
Accrued expenses									16,074	(3,534)	9,530
Income taxes									0	(5,611)	5,201
Other liabilities									1,164	17	778
Net cash flows from operating activities									35,796	62,939	23,849
Cash flows from investing activities:
Purchases of property and equipment									(9,419)	(5,126)	(6,205)
Stability acquisition									0	0	(7,631)
Fixed maturity securities redemption									0	0	3,000
Patent application costs									(609)	(271)	(842)
Net cash flows used in investing activities									(9,220)	(5,397)	(11,678)
Cash flows from financing activities:
Proceeds from exercise of stock options									3,555	11,987	3,494
Shares repurchased under repurchase plan									(7,572)	(68,263)	(10,378)
Shares repurchased for tax withholdings on vesting of restricted stock									(4,914)	(4,082)	(1,165)
Deferred financing costs											0
Payments under capital lease obligations									(3)	(29)	(102)
Net cash flows used in financing activities									(8,934)	(60,387)	(8,151)
Net change in cash									17,642	(2,845)	4,020
Cash and cash equivalents, beginning of year				$ 27,476				30,321	27,476	30,321	26,301
Cash and cash equivalents, end of year	$ 45,118				$ 27,476				$ 45,118	27,476	30,321
Previously Reported
Cash flows from operating activities:
Net income (loss)						$ 17,457	$ 8,069	4,327			11,974
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation											3,333
Amortization of intangible assets											2,127
Amortization of inventory fair value step-up											1,485
Amortization of deferred financing costs											181
Change in fair value of earn-out consideration											0
Share-based compensation											17,818
Change in deferred income taxes											(594)
Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in:
Accounts receivable											(11,396)
Inventory											(2,837)
Prepaid expenses											(2,400)
Other assets											(384)
Accounts payable											(3,665)
Accrued compensation											(2,669)
Accrued expenses											6,297
Income taxes											5,835
Other liabilities											723
Net cash flows from operating activities											25,828
Cash flows from investing activities:
Purchases of property and equipment											(6,269)
Stability acquisition											(7,631)
Fixed maturity securities redemption											3,000
Patent application costs											(842)
Net cash flows used in investing activities											(11,742)
Cash flows from financing activities:
Proceeds from exercise of stock options											3,494
Shares repurchased under repurchase plan											(10,378)
Shares repurchased for tax withholdings on vesting of restricted stock											(1,165)
Deferred financing costs											(30)
Payments under capital lease obligations											(102)
Net cash flows used in financing activities											(8,181)
Net change in cash											5,905
Cash and cash equivalents, beginning of year								34,391		34,391	28,486
Cash and cash equivalents, end of year											34,391
Adjustments
Cash flows from operating activities:
Net income (loss)											(11,584)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation											0
Amortization of intangible assets											10
Amortization of inventory fair value step-up											0
Amortization of deferred financing costs											(30)
Change in fair value of earn-out consideration											(1,650)
Share-based compensation											(86)
Change in deferred income taxes											(5,398)
Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in:
Accounts receivable											11,469
Inventory											1,942
Prepaid expenses											1,607
Other assets											(1,183)
Accounts payable											187
Accrued compensation											83
Accrued expenses											3,233
Income taxes											(634)
Other liabilities											55
Net cash flows from operating activities											(1,979)
Cash flows from investing activities:
Purchases of property and equipment											64
Stability acquisition											0
Fixed maturity securities redemption											0
Patent application costs											0
Net cash flows used in investing activities											64
Cash flows from financing activities:
Proceeds from exercise of stock options											0
Shares repurchased under repurchase plan											0
Shares repurchased for tax withholdings on vesting of restricted stock											0
Deferred financing costs											30
Payments under capital lease obligations											0
Net cash flows used in financing activities											30
Net change in cash											(1,885)
Cash and cash equivalents, beginning of year								$ (4,070)		$ (4,070)	(2,185)
Cash and cash equivalents, end of year											$ (4,070)